BNP Paribas Financial Markets Purchases New Stake in Progyny, Inc. (NASDAQ:PGNY)

BNP Paribas Financial Markets purchased a new stake in Progyny, Inc. (NASDAQ:PGNY - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 611,997 shares of the company's stock, valued at approximately $10,557,000. BNP Paribas Financial Markets owned about 0.72% of Progyny at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in shares of Progyny by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 8,692,132 shares of the company's stock valued at $149,939,000 after acquiring an additional 48,271 shares during the last quarter. Pacer Advisors Inc. grew its stake in Progyny by 47.5% in the fourth quarter. Pacer Advisors Inc. now owns 3,676,200 shares of the company's stock valued at $63,414,000 after purchasing an additional 1,183,558 shares in the last quarter. River Road Asset Management LLC acquired a new position in shares of Progyny during the 4th quarter worth approximately $25,529,000. Fort Washington Investment Advisors Inc. OH increased its position in shares of Progyny by 90.1% during the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company's stock worth $25,319,000 after purchasing an additional 695,740 shares during the last quarter. Finally, Barclays PLC raised its stake in shares of Progyny by 95.7% during the 4th quarter. Barclays PLC now owns 1,382,205 shares of the company's stock worth $23,843,000 after purchasing an additional 676,048 shares in the last quarter. 94.93% of the stock is owned by institutional investors.

Progyny Stock Up 0.4%

Shares of NASDAQ PGNY traded up $0.09 during mid-day trading on Thursday, reaching $21.95. 1,049,926 shares of the company were exchanged, compared to its average volume of 1,712,562. The stock has a market capitalization of $1.88 billion, a P/E ratio of 37.85, a P/E/G ratio of 2.39 and a beta of 1.37. The company's 50-day simple moving average is $21.99 and its 200-day simple moving average is $19.64. Progyny, Inc. has a twelve month low of $13.39 and a twelve month high of $30.42.

Progyny (NASDAQ:PGNY - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.45 by ($0.28). Progyny had a net margin of 5.03% and a return on equity of 11.36%. The company had revenue of $324.04 million during the quarter, compared to the consensus estimate of $307.86 million. During the same period in the prior year, the company earned $0.17 earnings per share. The firm's revenue was up 16.5% compared to the same quarter last year. As a group, equities research analysts expect that Progyny, Inc. will post 0.6 EPS for the current year.

Analysts Set New Price Targets

PGNY has been the subject of several analyst reports. BTIG Research raised shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 target price for the company in a research note on Monday, March 31st. Canaccord Genuity Group decreased their price objective on shares of Progyny from $23.00 to $21.00 and set a "hold" rating for the company in a research report on Monday. JPMorgan Chase & Co. boosted their price objective on shares of Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a research note on Tuesday, January 28th. Finally, Bank of America raised their target price on shares of Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a research note on Tuesday, February 11th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $23.45.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.